Insider Selling: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $95,563.00 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 7,351 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $95,563.00. Following the transaction, the insider now owns 232,681 shares in the company, valued at $3,024,853. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Thomas Gad also recently made the following trade(s):

• On Tuesday, May 21st, Thomas Gad sold 25,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $300,000.00.

Y-mAbs Therapeutics Price Performance

NASDAQ:YMAB opened at $12.22 on Friday. The business’s fifty day moving average price is $14.61 and its 200 day moving average price is $11.72. Y-mAbs Therapeutics, Inc. has a 12 month low of $4.60 and a 12 month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.17. The firm had revenue of $23.36 million for the quarter, compared to analyst estimates of $21.72 million. Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. As a group, equities research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on YMAB. Canaccord Genuity Group increased their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, March 4th. BMO Capital Markets increased their price objective on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. HC Wainwright increased their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Finally, Wedbush reiterated an “outperform” rating and issued a $18.00 price objective (up from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $17.33.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Large investors have recently bought and sold shares of the business. Trexquant Investment LP increased its holdings in Y-mAbs Therapeutics by 417.5% in the third quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock valued at $417,000 after buying an additional 61,785 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Y-mAbs Therapeutics by 24.0% during the third quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock worth $4,420,000 after purchasing an additional 157,173 shares during the last quarter. GSA Capital Partners LLP grew its holdings in shares of Y-mAbs Therapeutics by 208.3% during the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock worth $748,000 after purchasing an additional 92,765 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Y-mAbs Therapeutics during the fourth quarter worth about $34,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Y-mAbs Therapeutics by 258.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 82,131 shares of the company’s stock worth $448,000 after purchasing an additional 59,201 shares during the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.